Breakthrough: CHIATAI TIANQING's Anlotinib Hydrochloride Capsules and Bevacizumab Gain Approval for New Indications

In a significant development, CHIATAI TIANQING Pharmaceutical has achieved a major milestone with the acceptance of its new drug applications for Anlotinib Hydrochloride Capsules and Bevacizumab. These drugs have been granted approval for new indications by the China National Medical Products Administration's Center for Drug Evaluation (CDE). This groundbreaking approval opens up new treatment possibilities for patients with recurrent or metastatic endometrial cancer who have failed or are intolerant to previous chemotherapy regimens.

Anlotinib Hydrochloride Capsules:

Anlotinib Hydrochloride Capsules, an orally administered small-molecule multitargeted tyrosine kinase inhibitor (TKI), were independently developed by CHIATAI TIANQING Pharmaceutical. It received its initial approval from the China National Medical Products Administration in May 2018, making it the first drug approved for third-line treatment of advanced non-small cell lung cancer in China. Since then, Anlotinib Hydrochloride Capsules have received approvals for five additional indications: third-line small cell lung cancer, soft tissue sarcoma, medullary thyroid carcinoma, differentiated thyroid carcinoma, and now, in combination with Bevacizumab, for first-line treatment of small cell lung cancer.

Bevacizumab:

Bevacizumab, also known as TQB2450 injection, is a novel sequence of innovative fully humanized anti-PD-L1 monoclonal antibodies independently developed by CHIATAI TIANQING Pharmaceutical. In April 2022, Bevacizumab, in combination with Anlotinib Hydrochloride Capsules, was granted breakthrough therapy designation for the treatment of recurrent or metastatic endometrial cancer. In January 2023, Bevacizumab received formal approval from the CDE for first-line treatment of small cell lung cancer in combination with Anlotinib Hydrochloride Capsules. Now, with the recent acceptance of its new indication application, Bevacizumab has the potential to become the first PD-L1 inhibitor and small-molecule anti-angiogenesis agent approved for the treatment of recurrent or metastatic endometrial cancer, addressing an unmet clinical need and benefiting patients in China.

Endometrial Cancer:

Endometrial cancer ranks second among malignant tumors of the female reproductive system in China and is the most common gynecologic malignancy in developed countries. The incidence of endometrial cancer has been steadily increasing, particularly among younger populations, as high-fat and high-calorie diets and unhealthy lifestyles become more prevalent. Currently, platinum-based chemotherapy is the first-line treatment for endometrial cancer in China. However, for patients who experience disease progression after first-line treatment, there is currently no standard treatment available, resulting in limited clinical options and poor prognosis. The approval of Bevacizumab in combination with Anlotinib Hydrochloride Capsules offers new hope for patients with recurrent or metastatic endometrial cancer, addressing the urgent need for effective treatment options.

Future Prospects:

CHIATAI TIANQING Pharmaceutical is actively advancing the development of Bevacizumab and Anlotinib Hydrochloride Capsules, with ongoing Phase III clinical trials in various indications, including first-line renal cell carcinoma, first-line non-small cell lung cancer, and maintenance therapy after non-small cell lung cancer chemoradiotherapy. These efforts aim to provide new treatment options for a broader range of patients. The approval of these new indications marks a significant achievement for CHIATAI TIANQING Pharmaceutical, further solidifying its presence in the field of innovative therapies.

The acceptance of the new drug applications for Anlotinib Hydrochloride Capsules and Bevacizumab by the China National Medical Products Administration's Center for Drug Evaluation is a groundbreaking development in the field of oncology. This approval opens up new treatment possibilities for patients with recurrent or metastatic endometrial cancer, addressing an unmet clinical need. CHIATAI TIANQING Pharmaceutical's commitment to innovation and the development of novel therapies underscores its dedication to improving patient outcomes and revolutionizing cancer treatment.